These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
441 related articles for article (PubMed ID: 29085194)
41. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer. Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451 [TBL] [Abstract][Full Text] [Related]
42. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962 [TBL] [Abstract][Full Text] [Related]
43. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT. Klumpp B; Schwenzer NF; Gatidis S; Koenigsrainer I; Koenigsrainer A; Beckert S; Mueller M; Claussen CD; Pfannenberg C Rofo; 2014 Apr; 186(4):359-66. PubMed ID: 24683168 [TBL] [Abstract][Full Text] [Related]
44. Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma. Hamidian Jahromi A; Sangster G; Zibari G; Martin B; Chu Q; Takalkar A; Shi R; Shokouh-Amiri H JOP; 2013 Jul; 14(4):466-8. PubMed ID: 23846950 [TBL] [Abstract][Full Text] [Related]
45. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135 [TBL] [Abstract][Full Text] [Related]
47. 18 F-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer: a systematic review and meta-analysis. Wu LM; Hu JN; Hua J; Gu HY; Zhu J; Xu JR J Gastroenterol Hepatol; 2012 Mar; 27(3):472-80. PubMed ID: 21916986 [TBL] [Abstract][Full Text] [Related]
48. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Kubik-Huch RA; Dörffler W; von Schulthess GK; Marincek B; Köchli OR; Seifert B; Haller U; Steinert HC Eur Radiol; 2000; 10(5):761-7. PubMed ID: 10823629 [TBL] [Abstract][Full Text] [Related]
49. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels. Ozkan E; Soydal C; Araz M; Kir KM; Ibis E Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859 [TBL] [Abstract][Full Text] [Related]
50. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma. Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156 [TBL] [Abstract][Full Text] [Related]
51. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer]. Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351 [TBL] [Abstract][Full Text] [Related]
52. Value of 18F-FDG PET in the detection of peritoneal carcinomatosis. Suzuki A; Kawano T; Takahashi N; Lee J; Nakagami Y; Miyagi E; Hirahara F; Togo S; Shimada H; Inoue T Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1413-20. PubMed ID: 15205922 [TBL] [Abstract][Full Text] [Related]
53. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. Metser U; You J; McSweeney S; Freeman M; Hendler A AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157 [TBL] [Abstract][Full Text] [Related]
54. Role of F-18 FDG PET/CT in the follow-up of asymptomatic renal cell carcinoma patients for postoperative surveillance: based on conditional survival analysis. Park S; Lee HY; Lee S J Cancer Res Clin Oncol; 2022 Jan; 148(1):215-224. PubMed ID: 34106327 [TBL] [Abstract][Full Text] [Related]
55. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493 [TBL] [Abstract][Full Text] [Related]
56. Prognostic value of metabolic parameters on preoperative 18F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with stage III gastric cancer. Na SJ; o JH; Park JM; Lee HH; Lee SH; Song KY; Choi MG; Park CH Oncotarget; 2016 Sep; 7(39):63968-63980. PubMed ID: 27564108 [TBL] [Abstract][Full Text] [Related]
57. Clinical implication of FDG uptake of bone marrow on PET/CT in gastric cancer patients with surgical resection. Lee JW; Lee MS; Chung IK; Son MW; Cho YS; Lee SM World J Gastroenterol; 2017 Apr; 23(13):2385-2395. PubMed ID: 28428718 [TBL] [Abstract][Full Text] [Related]
58. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. Mochiki E; Kuwano H; Katoh H; Asao T; Oriuchi N; Endo K World J Surg; 2004 Mar; 28(3):247-53. PubMed ID: 14961197 [TBL] [Abstract][Full Text] [Related]
59. The peak-standardized uptake value (P-SUV) by preoperative positron emission tomography-computed tomography (PET-CT) is a useful indicator of lymph node metastasis in gastric cancer. Oh HH; Lee SE; Choi IS; Choi WJ; Yoon DS; Min HS; Ra YM; Moon JI; Kang YH J Surg Oncol; 2011 Oct; 104(5):530-3. PubMed ID: 21618250 [TBL] [Abstract][Full Text] [Related]
60. [Malignant tumor with false negative 18F-FDG PET image]. Dong MJ; Lin XT; Zhao J; Guan YH; Zuo CT; Chen X; Dai JZ; Jiang BD Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):713-7. PubMed ID: 17274383 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]